Apretude launch date?

When did Apretude (cabotegravir) launch in the U.S.?

Apretude (cabotegravir) was approved by the FDA and launched in the U.S. in 2021. [1]

What date was FDA approval, and when could sales start?

FDA approval came in January 2021, which is the key milestone that typically precedes U.S. product availability. After approval, commercial launch follows through distribution and pharmacy onboarding. [1]

Was Apretude available elsewhere before the U.S. launch?

The provided source ties Apretude’s launch to the U.S. timeline starting in 2021. If you need a country-by-country launch date (e.g., EU/UK), you’ll likely need additional region-specific regulatory documentation beyond the single launch reference. [1]

What exactly is Apretude used for at launch?

Apretude is used as a long-acting injectable for HIV prevention (pre-exposure prophylaxis, PrEP). The launch timing relates to its availability as an FDA-approved PrEP option. [1]

Sources
[1] https://www.drugpatentwatch.com/blog/apretude-cabotegravir-approval-launch-and-therapeutic-usage/